COPENHAGEN, Nov 29 (Reuters) - Novo Nordisk's
long-acting insulin blockbuster Tresiba has a safe
cardiovascular profile and reduces episodes of severely low
blood glucose levels in patients with type 2 diabetes, the
Denmark-based company said on Tuesday.
Read more
No comments:
Post a Comment